DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



[Micafungin for the treatment of neonatal invasive candidiasis]

Author(s): Infante-Lopez ME, Rojo-Conejo P

Affiliation(s): Servicio de Neonatologia, Hospital Universitario 12 de Octubre, Madrid, Espana. eleninf@hotmail.com

Publication date & source: 2009-03-31, Rev Iberoam Micol., 26(1):56-61. Epub 2009 May 7.

Publication type: Comparative Study; English Abstract; Review

BACKGROUND: In neonatal intensive care units, deep fungal disease due to Candida spp. are an important clinical problem, partly due to the increasing prevalence of Candida disease and also to the high associated and constant morbimortality; both factors are independently maintained though there has been a significant improvement in the management of neonatal patients. AIMS: To define the therapeutic use of micafungin for the treatment of neonatal invasive candidiasis. METHODS: We use a review of biomedic data bases namely Medline and EMBASE. CONCLUSIONS: Micafungin is the latest introduced echinocandin. It has a wide spectrum of activity and covers Candida albicans and non-albicans Candida species. It has scarce drugs interactions and is devoid of toxicity, being an attractive approach for the treatment of invasive candidiasis (without meningitis, endocarditis and endophthalmitis). Althought the European Medicines Agency approved in 2008 the use of Micafungin for the treatment of invasive candidiasis in children, the available clinical experience is limited and currently more clinical studies are warranted to define its efficacy and safety in neonates.

Page last updated: 2009-10-20

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017